Stocktoria
Lineage Cell Therapeutics, Inc. LCTX
NYSE American · XASE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1992-03-05
Lineage Cell Therapeutics, Inc. institutional holders (13F)
| Investor | Shares | Value | % of company |
|---|---|---|---|
| BlackRock Finance, Inc. | 9,559,466 | $9.5M | 3.93% |
| MILLENNIUM MANAGEMENT LLC | 5,561,374 | $8.8M | 2.29% |
| RENAISSANCE TECHNOLOGIES LLC | 2,125,100 | $3.4M | 0.87% |
| Point72 Asset Management, L.P. | 304,363 | $480,894 | 0.13% |
| CITADEL ADVISORS LLC | 166,248 | $262,672 | 0.07% |
| TWO SIGMA INVESTMENTS, LP | 88,585 | $139,964 | 0.04% |
% of company = reported 13F shares ÷ shares outstanding. Based on the latest filings; not every holder reports every quarter.
Source: SEC EDGAR filings · CIK 0000876343 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.